VREX — Varex Imaging Corporation

Is VREX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Neutral As of August 19, 2026

Varex Imaging Corporation (VREX) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $18.46. The rating moved from Overbought to Neutral on August 19, 2026.

AI analysis

Varex Imaging Corporation (VREX) benefits from durable demand for diagnostic and image-guided procedures that support recurring sales of detectors, X-ray tubes and imaging subsystems. Recent market rotation into growth names and positive social sentiment, together with insider activity, support near-term upside. The company’s diversified exposure across medical, security and industrial segments and potential adoption of AI-driven imaging workflows are constructive for order momentum and longer-term addressable market growth. Key considerations include the cyclical nature of capital spending, reimbursement and payer dynamics, competitive pressure from larger OEMs, and execution risks related to supply chains and regulatory developments. Near-term catalysts include stronger procedure volumes, new product ramps, and any visible improvement in backlog and margin trends.

Key factors

  • Favorable readthrough from stronger diagnostic and image-guided procedure demand supporting component and detector sales
  • Exposure to MRI/CT/X-ray and industrial imaging markets with recurring replacement and upgrade cycles
  • Recent constructive market sentiment and insider activity (Form 4) supporting near-term technical momentum
  • Potential AI-enabled diagnostics tailwinds that increase procurement of imaging hardware and software
  • Reasonable valuation relative to high-growth peers (implied upside from modest multiple expansion)
  • Diversified end-market exposure (medical, security, industrial) helping smooth cyclical fluctuations

Risks

  • Capital-equipment spending is cyclical; procedure volumes and hospital budgets can compress demand
  • Reimbursement, payer rationalization and healthcare macro headwinds could pressure volumes and pricing
  • Competition from larger OEMs and vertically integrated suppliers could compress margins
  • Regulatory, privacy and digital-health enforcement risks could slow adoption of some distribution channels
  • Supply-chain disruptions or component shortages could delay shipments and revenue recognition
  • Currency, macroeconomic and geopolitical volatility could negatively impact international sales

See today's live rating, score and targets

Members see the live hourly rating for VREX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.